Centivax develops broad-spectrum vaccines and therapeutic antibodies targeting infectious diseases and venomous threats. The company advances a universal influenza vaccine, antibody-based antivenoms effective across multiple snake species, and broad-spectrum anti‑infective programs against drug-resistant bacteria. Led by a team of specialists—including a computational immuno-engineer, veteran vaccine developer, herpetology expert, and molecular immunologist—Centivax integrates computational methods with laboratory and in‑vivo research. Its universal flu vaccine has completed preclinical studies in various animal models and is preparing for human trials in 2026, supported by the Gates Foundation. The antivenom program leverages unique human immunity insights to create next‑generation treatments for snakebite envenoming.
